Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs.
Psychiatry research September 1, 2024 Qinghua Guo, Libo Guo, Yong Wang et al. 19 citations
A network meta-analysis of 72 randomized controlled trials with 12,105 participants found that electroconvulsive therapy (ECT), ketamine, esketamine, and psilocybin are superior first-line treatments for treatment-resistant depression (TRD) due to their optimal balance of effectiveness and tolerability. Brexpiprazole and quetiapine showed no significant efficacy over placebo in response rates. Esketamine and psilocybin exhibited lower tolerability. The findings advocate for ECT, ketamine, esketamine, and psilocybin as preferred treatments, guiding clinical practice with evidence-based recommendations for enhancing treatment outcomes.